225 related articles for article (PubMed ID: 30143953)
1. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.
Mennini FS; Bini C; Marcellusi A; Del Vecchio M
Clin Drug Investig; 2018 Oct; 38(10):967-976. PubMed ID: 30143953
[TBL] [Abstract][Full Text] [Related]
2. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
3. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
4. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
6. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
7. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
8. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Bastiaannet E; Battisti N; Loh KP; de Glas N; Soto-Perez-de-Celis E; Baldini C; Kapiteijn E; Lichtman S
J Geriatr Oncol; 2019 May; 10(3):389-397. PubMed ID: 30025821
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
[TBL] [Abstract][Full Text] [Related]
10. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
11. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
15. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
16. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
18. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]